Skip to main content

2014 | OriginalPaper | Buchkapitel

13. Alternative Protein Scaffolds for Molecular Imaging and Therapy

verfasst von : Benjamin J. Hackel

Erschienen in: Engineering in Translational Medicine

Verlag: Springer London

Aktivieren Sie unsere intelligente Suche um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Molecular targeting has tremendous potential to enhance the specificity and sensitivity of diagnostics and the safety and potency of therapeutics, as well as to induce unique and precise biological responses. Effective targeting requires specific binding of appropriate affinity, conjugation of effectors (e.g., toxins, radioisotopes, or fusion proteins) as needed, stable maintenance of activity, and effective delivery physiologically. Ideally, solutions to these challenges will be efficiently implemented for a multitude of molecular targets unique to the relevant pathophysiology. Protein scaffolds, molecular frameworks amenable to local diversity to introduce specific binding while retaining favorable biophysical characteristics, offer an intriguing general solution. While antibodies and their derivatives offer viable options, a host of alternative topologies prove superior in stability, size, production, and/or conjugation. Validated scaffolds include the fibronectin domain, knottin, designed ankyrin repeat protein, anticalin, and affibody among others. These scaffolds have demonstrated efficacy in preclinical animal models and, in some cases, clinical trials in therapy or imaging. These translational developments will be reviewed here. The future is bright for both antibodies and their alternatives. Research should be undertaken to identify the most efficacious scaffold for each individual clinical indication and application.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Literatur
2.
Zurück zum Zitat Yuan F, Dellian M, Fukumura D et al (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3756 Yuan F, Dellian M, Fukumura D et al (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3756
4.
Zurück zum Zitat Binz HK, Amstutz P, Plückthun A (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23:1257–1268. doi:10.1038/nbt1127 CrossRef Binz HK, Amstutz P, Plückthun A (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23:1257–1268. doi:10.​1038/​nbt1127 CrossRef
13.
14.
Zurück zum Zitat Batori V, Koide A, Koide S (2002) Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. Protein Eng 15:1015–1020CrossRef Batori V, Koide A, Koide S (2002) Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. Protein Eng 15:1015–1020CrossRef
15.
Zurück zum Zitat Parker MH, Chen Y, Danehy F et al (2005) Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel 18:435–444. doi:10.1093/protein/gzi050 CrossRef Parker MH, Chen Y, Danehy F et al (2005) Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel 18:435–444. doi:10.​1093/​protein/​gzi050 CrossRef
16.
Zurück zum Zitat Hackel BJ, Wittrup KD (2010) The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. Protein Eng Des Sel 23:211–219. doi:10.1093/protein/gzp083 CrossRef Hackel BJ, Wittrup KD (2010) The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. Protein Eng Des Sel 23:211–219. doi:10.​1093/​protein/​gzp083 CrossRef
18.
Zurück zum Zitat Koide A, Jordan MR, Horner SR et al (2001) Stabilization of a fibronectin type III domain by the removal of unfavorable electrostatic interactions on the protein surface. Biochemistry 40:10326–10333CrossRef Koide A, Jordan MR, Horner SR et al (2001) Stabilization of a fibronectin type III domain by the removal of unfavorable electrostatic interactions on the protein surface. Biochemistry 40:10326–10333CrossRef
20.
Zurück zum Zitat Mamluk R, Carvajal IM, Morse BA et al (2010) Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. mAbs, vol 2, pp 199–208 Mamluk R, Carvajal IM, Morse BA et al (2010) Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. mAbs, vol 2, pp 199–208
21.
Zurück zum Zitat Dineen SP, Sullivan LA, Beck AW et al (2008) The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 8:352. doi:10.1186/1471-2407-8-352 CrossRef Dineen SP, Sullivan LA, Beck AW et al (2008) The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 8:352. doi:10.​1186/​1471-2407-8-352 CrossRef
22.
Zurück zum Zitat Ackermann M, Carvajal IM, Morse BA et al (2011) Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts. Int J Oncol 38:71–80. doi:10.3892/ijo_00000825 Ackermann M, Carvajal IM, Morse BA et al (2011) Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts. Int J Oncol 38:71–80. doi:10.​3892/​ijo_​00000825
23.
Zurück zum Zitat Waters JD, Sanchez C, Sahin A et al (2012) CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. J Neurooncol 110:37–48. doi:10.1007/s11060-012-0948-7 CrossRef Waters JD, Sanchez C, Sahin A et al (2012) CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. J Neurooncol 110:37–48. doi:10.​1007/​s11060-012-0948-7 CrossRef
24.
Zurück zum Zitat Tolcher AW, Sweeney CJ, Papadopoulos K et al (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17:363–371. doi:10.1158/1078-0432.CCR-10-1411 CrossRef Tolcher AW, Sweeney CJ, Papadopoulos K et al (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17:363–371. doi:10.​1158/​1078-0432.​CCR-10-1411 CrossRef
25.
Zurück zum Zitat Paschold EH, Mazieres J, Lena H et al (2012) A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 30:a7584 Paschold EH, Mazieres J, Lena H et al (2012) A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 30:a7584
26.
Zurück zum Zitat Ackermann M, Morse BA, Delventhal V et al (2012) Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture. Angiogenesis 15:685–695. doi:10.1007/s10456-012-9294-9 CrossRef Ackermann M, Morse BA, Delventhal V et al (2012) Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture. Angiogenesis 15:685–695. doi:10.​1007/​s10456-012-9294-9 CrossRef
27.
Zurück zum Zitat Emanuel SL, Engle LJ, Chao G et al. (2011) A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. mAbs vol 3, pp 38–48 Emanuel SL, Engle LJ, Chao G et al. (2011) A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. mAbs vol 3, pp 38–48
28.
29.
30.
31.
Zurück zum Zitat Hackel BJ, Sathirachinda A, Gambhir SS (2012) Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution. Protein Eng Des Sel 25:639–647. doi:10.1093/protein/gzs036 CrossRef Hackel BJ, Sathirachinda A, Gambhir SS (2012) Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution. Protein Eng Des Sel 25:639–647. doi:10.​1093/​protein/​gzs036 CrossRef
32.
Zurück zum Zitat Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD (2011) Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem 286:4165–4172. doi:10.1074/jbc.M110.186973 CrossRef Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD (2011) Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem 286:4165–4172. doi:10.​1074/​jbc.​M110.​186973 CrossRef
34.
Zurück zum Zitat Colgrave ML, Craik DJ (2004) Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 43:5965–5975. doi:10.1021/bi049711q CrossRef Colgrave ML, Craik DJ (2004) Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 43:5965–5975. doi:10.​1021/​bi049711q CrossRef
35.
37.
38.
Zurück zum Zitat Perez-Pinzon MA, Yenari MA, Sun GH et al (1997) SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J Neurol Sci 153:25–31CrossRef Perez-Pinzon MA, Yenari MA, Sun GH et al (1997) SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J Neurol Sci 153:25–31CrossRef
39.
Zurück zum Zitat Joppa MA, Gogas KR, Foster AC, Markison S (2007) Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 28:636–642. doi:10.1016/j.peptides.2006.11.021 CrossRef Joppa MA, Gogas KR, Foster AC, Markison S (2007) Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 28:636–642. doi:10.​1016/​j.​peptides.​2006.​11.​021 CrossRef
40.
Zurück zum Zitat Hockaday DC, Shen S, Fiveash J et al (2005) Imaging glioma extent with 131I-TM-601. J Nucl Med 46:580–586 Hockaday DC, Shen S, Fiveash J et al (2005) Imaging glioma extent with 131I-TM-601. J Nucl Med 46:580–586
46.
Zurück zum Zitat Kimura RH, Levin AM, Cochran FV, Cochran JR (2009) Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins 77:359–369. doi:10.1002/prot.22441 CrossRef Kimura RH, Levin AM, Cochran FV, Cochran JR (2009) Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins 77:359–369. doi:10.​1002/​prot.​22441 CrossRef
48.
Zurück zum Zitat Kimura RH, Miao Z, Cheng Z et al (2010) A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem 21:436–444. doi:10.1021/bc9003102 CrossRef Kimura RH, Miao Z, Cheng Z et al (2010) A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem 21:436–444. doi:10.​1021/​bc9003102 CrossRef
49.
Zurück zum Zitat Miao Z, Ren G, HHongguang L (2009) An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem 20:2342–2347. doi:10.1021/bc900361g CrossRef Miao Z, Ren G, HHongguang L (2009) An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem 20:2342–2347. doi:10.​1021/​bc900361g CrossRef
51.
Zurück zum Zitat Willmann JK, Kimura RH, Deshpande N et al (2010) Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 51:433–440. doi:10.2967/jnumed.109.068007 CrossRef Willmann JK, Kimura RH, Deshpande N et al (2010) Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 51:433–440. doi:10.​2967/​jnumed.​109.​068007 CrossRef
53.
Zurück zum Zitat Jiang L, Kimura RH, Miao Z et al (2010) Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med 51:251–258. doi:10.2967/jnumed.109.069831 CrossRef Jiang L, Kimura RH, Miao Z et al (2010) Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med 51:251–258. doi:10.​2967/​jnumed.​109.​069831 CrossRef
54.
Zurück zum Zitat Jiang L, Miao Z, Kimura RH et al (2012) 111In-labeled cystine-knot peptides based on the agouti-related protein for targeting tumor angiogenesis. J Biomed Biotechnol 2012:1–8. doi:10.1002/ijc.23575 Jiang L, Miao Z, Kimura RH et al (2012) 111In-labeled cystine-knot peptides based on the agouti-related protein for targeting tumor angiogenesis. J Biomed Biotechnol 2012:1–8. doi:10.​1002/​ijc.​23575
56.
Zurück zum Zitat Kimura RH, Teed R, Hackel BJ et al (2012) Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res 18:839–849. doi:10.1158/1078-0432.CCR-11-1116 CrossRef Kimura RH, Teed R, Hackel BJ et al (2012) Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res 18:839–849. doi:10.​1158/​1078-0432.​CCR-11-1116 CrossRef
57.
Zurück zum Zitat Hackel BJ, Kimura RH, Miao Z et al (2013) 18F-labeled cystine knot peptides for PET imaging of integrin αvβ6. J Nucl Med 54(7):1101–1105 Hackel BJ, Kimura RH, Miao Z et al (2013) 18F-labeled cystine knot peptides for PET imaging of integrin αvβ6. J Nucl Med 54(7):1101–1105
58.
Zurück zum Zitat Jiang L, Miao Z, Kimura RH et al (2011) Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging 38:613–622. doi:10.1007/s00259-010-1684-x CrossRef Jiang L, Miao Z, Kimura RH et al (2011) Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging 38:613–622. doi:10.​1007/​s00259-010-1684-x CrossRef
59.
60.
Zurück zum Zitat Souriau C, Chiche L, Irving R, Hudson P (2005) New binding specificities derived from Min-23, a small cystine-stabilized peptidic scaffold. Biochemistry 44:7143–7155. doi:10.1021/bi0481592 CrossRef Souriau C, Chiche L, Irving R, Hudson P (2005) New binding specificities derived from Min-23, a small cystine-stabilized peptidic scaffold. Biochemistry 44:7143–7155. doi:10.​1021/​bi0481592 CrossRef
62.
63.
Zurück zum Zitat Theurillat J-P, Dreier B, Nagy-Davidescu G et al (2010) Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Mod Pathol 23:1289–1297. doi:10.1038/modpathol.2010.103 CrossRef Theurillat J-P, Dreier B, Nagy-Davidescu G et al (2010) Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Mod Pathol 23:1289–1297. doi:10.​1038/​modpathol.​2010.​103 CrossRef
65.
Zurück zum Zitat Friedrich K, Hanauer JR, Prüfer S et al (2013) DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther. doi:10.1038/mt.2013.16 Friedrich K, Hanauer JR, Prüfer S et al (2013) DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther. doi:10.​1038/​mt.​2013.​16
66.
Zurück zum Zitat Martin-Killias P, Patricia M-K, Stefan N et al (2011) A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res 17:100–110. doi:10.1158/1078-0432.CCR-10-1303 CrossRef Martin-Killias P, Patricia M-K, Stefan N et al (2011) A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res 17:100–110. doi:10.​1158/​1078-0432.​CCR-10-1303 CrossRef
67.
Zurück zum Zitat Wolf S, Souied EH, Mauget-Faysse M et al (2011) Phase I MP0112 wet AMD study: results of a single escalating dose study with DARPin MP0112 in wet AMD. 2011 annual meeting of the association for research in vision and ophthalmology, vol 1655 Wolf S, Souied EH, Mauget-Faysse M et al (2011) Phase I MP0112 wet AMD study: results of a single escalating dose study with DARPin MP0112 in wet AMD. 2011 annual meeting of the association for research in vision and ophthalmology, vol 1655
68.
Zurück zum Zitat Campochiaro PA, Channa R, Berger BB et al (2013) Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol 155(697–704):e2. doi:10.1016/j.ajo.2012.09.032 Campochiaro PA, Channa R, Berger BB et al (2013) Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol 155(697–704):e2. doi:10.​1016/​j.​ajo.​2012.​09.​032
69.
Zurück zum Zitat Kim HJ, Eichinger A, Skerra A (2009) High-affinity recognition of lanthanide (III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc 131:3565–3576. doi:10.1021/ja806857r CrossRef Kim HJ, Eichinger A, Skerra A (2009) High-affinity recognition of lanthanide (III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc 131:3565–3576. doi:10.​1021/​ja806857r CrossRef
70.
Zurück zum Zitat Schönfeld D, Matschiner G, Chatwell L et al (2009) An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci 106:8198–8203. doi:10.1073/pnas.0813399106 CrossRef Schönfeld D, Matschiner G, Chatwell L et al (2009) An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci 106:8198–8203. doi:10.​1073/​pnas.​0813399106 CrossRef
71.
Zurück zum Zitat Nunn MA, Sharma A, Paesen GC et al (2005) Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol 174:2084–2091 Nunn MA, Sharma A, Paesen GC et al (2005) Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol 174:2084–2091
73.
74.
Zurück zum Zitat Carrera-Marin AL, Romay-Penabad Z, Machin S et al (2011) C5 inhibitor rEV576 ameliorates in vivo effects of antiphospholipid antibodies. Arthritis and Rheumatism 63:S5–S5 Carrera-Marin AL, Romay-Penabad Z, Machin S et al (2011) C5 inhibitor rEV576 ameliorates in vivo effects of antiphospholipid antibodies. Arthritis and Rheumatism 63:S5–S5
75.
Zurück zum Zitat Couillin I, Maillet I, Vargaftig BB et al (2004) Arthropod-derived histamine-binding protein prevents murine allergic asthma. J Immunol 173:3281–3286 Couillin I, Maillet I, Vargaftig BB et al (2004) Arthropod-derived histamine-binding protein prevents murine allergic asthma. J Immunol 173:3281–3286
77.
79.
81.
Zurück zum Zitat Mross K, Fischer R, Richly H et al (2011) Abstract A212: first in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: results of a dose escalation study. Mol Cancer Ther 10:A212–A212. doi:10.1158/1535-7163.TARG-11-A212 Mross K, Fischer R, Richly H et al (2011) Abstract A212: first in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: results of a dose escalation study. Mol Cancer Ther 10:A212–A212. doi:10.​1158/​1535-7163.​TARG-11-A212
82.
Zurück zum Zitat Steiner M, Gutbrodt K, Krall N, Neri D (2013) Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications. Bioconjug Chem 24:234–241. doi:10.1021/bc300567a CrossRef Steiner M, Gutbrodt K, Krall N, Neri D (2013) Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications. Bioconjug Chem 24:234–241. doi:10.​1021/​bc300567a CrossRef
83.
Zurück zum Zitat Lendel C, Dincbas-Renqvist V, Flores A et al (2004) Biophysical characterization of Z(SPA-1)–a phage-display selected binder to protein A. Protein Sci 13:2078–2088. doi:10.1110/ps.04728604 CrossRef Lendel C, Dincbas-Renqvist V, Flores A et al (2004) Biophysical characterization of Z(SPA-1)–a phage-display selected binder to protein A. Protein Sci 13:2078–2088. doi:10.​1110/​ps.​04728604 CrossRef
85.
Zurück zum Zitat Lundberg E, Brismar H, Gräslund T (2009) Selection and characterization of Affibody ligands to the transcription factor c-Jun. Biotechnol Appl Biochem 52:17–27. doi:10.1042/BA20070178 CrossRef Lundberg E, Brismar H, Gräslund T (2009) Selection and characterization of Affibody ligands to the transcription factor c-Jun. Biotechnol Appl Biochem 52:17–27. doi:10.​1042/​BA20070178 CrossRef
87.
88.
Zurück zum Zitat Kronqvist N, Malm M, Göstring L et al (2011) Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules Kronqvist N, Malm M, Göstring L et al (2011) Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules
91.
Zurück zum Zitat Miao Z, Ren G, Jiang L et al (2011) A novel (18)F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-011-1879-9 Miao Z, Ren G, Jiang L et al (2011) A novel (18)F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor. Eur J Nucl Med Mol Imaging. doi:10.​1007/​s00259-011-1879-9
92.
Zurück zum Zitat Ahlgren S, Tolmachev V (2010) Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 11:581–589CrossRef Ahlgren S, Tolmachev V (2010) Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 11:581–589CrossRef
95.
Zurück zum Zitat Baum RP, Prasad V, Müller D et al (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68 Ga-labeled affibody molecules. J Nucl Med 51:892–897. doi:10.2967/jnumed.109.073239 CrossRef Baum RP, Prasad V, Müller D et al (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68 Ga-labeled affibody molecules. J Nucl Med 51:892–897. doi:10.​2967/​jnumed.​109.​073239 CrossRef
97.
Zurück zum Zitat Andersen JT, Pehrson R, Tolmachev V et al (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 286:5234–5241. doi:10.1074/jbc.M110.164848 CrossRef Andersen JT, Pehrson R, Tolmachev V et al (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 286:5234–5241. doi:10.​1074/​jbc.​M110.​164848 CrossRef
98.
Zurück zum Zitat Steffen A-C, Almqvist Y, Chyan M-K et al (2007) Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. Oncol Rep 17:1141–1147 Steffen A-C, Almqvist Y, Chyan M-K et al (2007) Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. Oncol Rep 17:1141–1147
99.
Zurück zum Zitat Myhre S, Henning P, Friedman M et al (2009) Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber. Gene Ther 16:252–261. doi:10.1038/gt.2008.160 CrossRef Myhre S, Henning P, Friedman M et al (2009) Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber. Gene Ther 16:252–261. doi:10.​1038/​gt.​2008.​160 CrossRef
100.
Zurück zum Zitat Lehmann A (2008) Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther 8:1187–1199. doi:10.1517/14712598.8.8.1187 CrossRef Lehmann A (2008) Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther 8:1187–1199. doi:10.​1517/​14712598.​8.​8.​1187 CrossRef
102.
Zurück zum Zitat Silverman J, Liu Q, Lu Q et al (2005) Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23:1556–1561. doi:10.1038/nbt1166 CrossRef Silverman J, Liu Q, Lu Q et al (2005) Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23:1556–1561. doi:10.​1038/​nbt1166 CrossRef
Metadaten
Titel
Alternative Protein Scaffolds for Molecular Imaging and Therapy
verfasst von
Benjamin J. Hackel
Copyright-Jahr
2014
Verlag
Springer London
DOI
https://doi.org/10.1007/978-1-4471-4372-7_13

Neuer Inhalt